

References

I-35

1. Deohar A, Branu J, Inman R, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE *Annals of the Rheumatic Diseases*. 2015;74:757–761.
2. Ward M, Deodhar A, Akl E, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. *Arthritis Rheumatology*. 2015.
3. Smolen, Kay J, Doyle M, et al. 2015. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. *Arthritis Research & Therapy*. 2015;17:14.
4. Ramiro S, Smolen J, Landewé, et al. Pharmacological treatment of psoriatic arthritis: A systematic literature review for the 2015 update of the European League against Rheumatism (EULAR) recommendations for the management of psoriatic *Annals of the Rheumatic Diseases*. 2015;0:1–9.
5. Tursi A, Allegretta L, Buccianti N, et al. Effectiveness and safety of golimumab in treating outpatient ulcerative colitis: a real-life prospective, multicentre, observational study in primary inflammatory bowel diseases *J Gastrointest Liver Dis*. 2017;239-244.
6. Svedbom A, Storck C, Kachroo S, et al. Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic *Patient Preference and Adherence*. 2017;719–729.
7. MICROMEDEX®SOLUTIONS 2019. Golimumab.
8. Clinical Pharmacology [database online]. Tampa FL: Gold Standard, Inc. Golimumab. 2019.

9. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT- 0009(SR).
10. Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. *Arthritis & Rheumatology*. 2017;69(11):2151-21.
11. Simponi (golimumab) injection, for subcutaneous use [package insert]. Jansen Biotech, Inc. Horsham, PA. Revised 02/2018.
12. Simponi Aria (golimumab) injection, for intravenous use [package insert]. Jansen Biotech, Inc. Horsham, PA. Revised 05/2018.
13. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol*. 2019;114:384-413.
14. Braun J, Vandenberg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis*. 2011;70:896–904.
15. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. *J Am Acad Dermatol*. 2008;58:826-50.
16. Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group. *Gastroenterology*. 2019;156:1508-1524.
17. Singh JA, Saag KG, Bridges Jr SL, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research*. 2015;1-25.

18. Singh JA, Guyatt G, Ogdie A, et al. 2018 American college of rheumatology/national psoriasis foundation guideline for the treatment of psoriatic arthritis. *Journal of Psoriasis and Psoriatic Arthritis*. 2019; 4(1):31-58.

19. Menter A, Strober BE, Kaplan DH. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2019;80:1029-72.